Gensia's GenESA receives approval in the U.K.
Gensia Inc. on Friday said it received U.K. approval of its GenESA System to pharmacologically stress the heart. The system, which uses computer-controlled delivery of arbutamine, is indicated for use in the diagnosis of coronary artery disease in conjunction with electrocardiography (ECG), echocardiography and radionuclide imaging for patients who can't exercise adequately. GNSA's Gensia Europe Ltd. subsidiary plans to begin sales late this quarter or early in the second quarter with a 5-8 person sales force. The device, developed by Protocol Systems Inc., will cost $6,000-8,000.